Toggle Health Problems and D

Vitamin D is one of 14 ways proven to treat COVID-19 – July 2021

Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review

Int J Environ Res Public Health,. 2021 Jul 5;18(13):7212. doi: 10.3390/ijerph18137212.
Reinaldo B Bestetti 1, Rosemary Furlan-Daniel 1, Vinicius M R Silva 1

Placebo-controlled Bamlanivimab +etesivimabReduced viral load
Open-label Inhaled Budesonide hospitalization and number of visits to emergency department
Placebo-controlled Vitamin D Reduced viral load
Open-label Favirapir Shortened time to cure
Open-label Interferon beta-1
+Lopinavir + Ritonavir.
Shortened time to viral clearance
Placebo-controlled Colchicine Reduced the composite endpoint of death or hospitalization
Placebo-controlled Fluvoxamine Reduced clinical deterioration
Placebo-controlled Nitazoxamide Reduced viral load
Placebo-controlled Ivermectine May have shortened time to viral clearance
Placebo-controlled Levamisole May reduce clinical symptoms
Open-label Hypertonic saline Reduced clinical symptoms
Open-label Remdesivir Improved clinical status
Placebo-controlled REGN-COV2Decreased viral load and improved clinical status
Placebo-controlled Peginterferon lambda Decreased viral load

Ivermectin and COVID-19 - many studies
COVID-19 risks reduced by Vitamin D, Magnesium, Zinc, Resveratrol, Omega-3, etc. (auto-updated)
COVID-19 doctors not allowed to use treatments that work - Dr McCullough Video and transcript May 2021
After 57 years FDA is declaring NAC to be a drug (note: 16 trials are investigating NAC ability to fight COVID-19) – June 2021
AI is examining 170,000 potential COVID-19 treatments, Vitamin D is one of only 6 found – Sept 4, 2020

Vitamin D is amoung the many treatments that can also prevent

COVID-19 treated by Vitamin D - studies, reports, videos

5 most-recently changed Virus entries

Vitamin D meta-analyses for VIRUS

RecoveryTrial.net is trying many (prescription) treatments

Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin,: Convalescent plasma, Tocilizumab. Immunoglobulin, Synthetic neutralising antibodies, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, Infliximab, High Dose Corticosteroid
Suspect they are funded by Big Pharma - virtually all are patented and required a prescription

 Download the PDF from VitaminDWiki

Mild to moderate COVID-19 can be found in about 80% of patients. Although mortality is low, mild to moderate COVID-19 may progress to severe or even critical stages in about one week. This poses a substantial burden on the health care system, and ultimately culminates in death or incapacitation and hospitalization. Therefore, pharmacological treatment is paramount for patients with this condition, especially those with recognized risk factors to disease progression. We conducted a comprehensive review in the medical literature searching for randomized studies carried out in patients with mild to moderate COVID-19. A total of 14 randomized studies were identified, enrolling a total of 6848 patients. Nine studies (64%) were randomized, placebo-controlled trials, whereas five were open-label randomized trials (35%). We observed that Bamlanivimab and nitazoxanide reduced viral load, whereas ivermectin may have shortened time to viral clearance; Interferon Beta-1 reduced time to viral clearance and vitamin D reduced viral load; Favirapir, peginterferon, and levamisole improved clinical symptoms, whereas fluvoxamine halted disease progression; inhaled budesonide reduced the number of hospitalizations and visits to emergency departments; colchicine reduced the number of deaths and hospitalizations. Collectively, therefore, these findings show that treatment of early COVID-19 may be associated with reduced viral load, thus potentially decreasing disease spread in the community. Moreover, treatment of patients with mild to moderate COVID-19 may also be associated with improved clinical symptoms, hospitalization, and disease progression. We suggest that colchicine, inhaled budesonide, and nitazoxanide, along with nonpharmacological measures, based on efficacy and costs, may be used to mitigate the effects of the COVID-19 pandemic in middle-income countries.

Created by admin. Last Modification: Saturday August 21, 2021 16:48:14 GMT-0000 by admin. (Version 12)

Attached files

ID Name Comment Uploaded Size Downloads
15936 viral load decreases.pdf admin 20 Jul, 2021 341.09 Kb 272